Pharming Group N.V. has announced its preliminary financial results for the third quarter of 2026, showcasing a significant increase in revenues that exceeded market expectations. The company reported total revenues of approximately $117.6 million, marking a 21% increase compared to the same quarter last year. This strong performance is attributed to the continued demand for its flagship products, RUCONEST and Joenja.
Pharming Group, headquartered in Leiden, Netherlands, is a biotechnology company focused on developing and commercializing innovative medicines for rare immune and genetic diseases. The company operates under the ticker symbols PHAR on Nasdaq and PHARM on Euronext Amsterdam. Pharming is categorized under the SIC code 2834, which pertains to pharmaceutical preparations.
According to the recent filing, Pharming's total operating expenses for the third quarter were approximately $74.6 million, consistent with the previous year. The company has also tightened its total revenue guidance for 2026, now expecting between $380 million and $390 million, compared to the previous range of $375 million to $395 million.
The filing indicates that the revenue growth for the third quarter was driven primarily by RUCONEST, which generated about $93.8 million, a 14% increase from Q3 2025. Joenja also saw substantial growth, bringing in approximately $23.8 million, reflecting a 58% increase compared to the same quarter last year. This growth highlights the successful recovery of demand for RUCONEST in the U.S. market and the expanding international demand for Joenja.
Pharming's results may impact various stakeholders, including investors, analysts, and healthcare professionals, as the company prepares for a conference call on October 27, 2026, to discuss its full financial results and provide further updates on its business performance.
The filing does not specify any immediate next steps beyond the upcoming conference call, where Pharming will share more detailed financial results and insights into its business strategy moving forward.